Vusolimogene Oderparepvec-wtpg (Tudriqev) Coverage Criteria
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.774 alerts
Get alerted when Policy CP.PHAR.774 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Tudriqev, including initial and continuation therapy, for QualChoice commercial, HIM/ICHRA, and Medicaid members.
Disease progression after treatment with an anti-PD-1-containing regimen is now required.
Coverage criteria were revised to reflect the FDA-approved indication.
The ICHRA line of business was added.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.